Efficacy of a dengue vaccine candidate (TAK-003) in healthy children and adolescents two years after vaccination - PubMed

TAK-003 demonstrated continued benefit independent of baseline serostatus in reducing dengue with some decline in efficacy during the second year. Three-year data will be important to see if efficacy stabilizes or declines further.